TY - JOUR
T1 - Crucial considerations for pipelines to validate circulating biomarkers for breast cancer
AU - Ewaisha, Radwa
AU - Gawryletz, Chelsea D.
AU - Anderson, Karen
N1 - Funding Information:
The paper was funded by the Early Detection Research Network U01 CA117374. KS Anderson is a consultant for and has stock options with Provista Diagnostics and is on an institutional patent submission for breast cancer serologic biomarkers. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Publisher Copyright:
© 2016 Taylor & Francis.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.
AB - Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.
KW - Biomarker discovery
KW - PRoBE principles
KW - autoantibodies
KW - breast cancer
KW - early detection
KW - pipeline
KW - validation
UR - http://www.scopus.com/inward/record.url?scp=84957437326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957437326&partnerID=8YFLogxK
U2 - 10.1586/14789450.2016.1132170
DO - 10.1586/14789450.2016.1132170
M3 - Review article
C2 - 26653344
AN - SCOPUS:84957437326
SN - 1478-9450
VL - 13
SP - 201
EP - 211
JO - Expert Review of Proteomics
JF - Expert Review of Proteomics
IS - 2
ER -